<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02249689</url>
  </required_header>
  <id_info>
    <org_study_id>CM-001-001</org_study_id>
    <nct_id>NCT02249689</nct_id>
  </id_info>
  <brief_title>Three-month Clinical Evaluation of Silicone Hydrogel Definitive 65 Contact Lenses</brief_title>
  <official_title>Three-month Clinical Evaluation of Silicone Hydrogel Definitive 65 Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contamac Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hartwig Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Contamac Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of different contact lens materials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a 3-month, open-label, bilateral, parallel-group, randomised, daily wear study.&#xD;
      Two-thirds of the subjects will wear the Test lenses in both eyes, and one-third will wear&#xD;
      the Control lenses in both eyes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>questionnaire addressing subjective comfort and wear time</measure>
    <time_frame>subjects will be followed-up for three months</time_frame>
    <description>Subjects rated on a scale from 1 to 10, where 1 was 'poor' and 10 was 'excellent'.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>limbal redness - ocular biomicroscopy</measure>
    <time_frame>subjects will be followed-up for three months</time_frame>
    <description>Findings were graded based on a grading scale which ranged from 0 to 4, where 0 is none, 1 is trace, 2 is mild, 3 is moderate and 4 is severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corneal staining - ocular biomicroscopy</measure>
    <time_frame>subjects will be followed-up for three months</time_frame>
    <description>Findings were graded based on a grading scale which ranged from 0 to 4, where 0 is none, 1 is trace, 2 is mild, 3 is moderate and 4 is severe.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Ametropia</condition>
  <arm_group>
    <arm_group_label>Definitive 65</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Test product were the Definitive 65 (Filcon V4) lenses. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Definitive 74</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Control product was the commercially available Definitive 74 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Definitive 65</intervention_name>
    <arm_group_label>Definitive 65</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Definitive 74</intervention_name>
    <arm_group_label>Definitive 74</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  willing and able to sign the informed consent form&#xD;
&#xD;
          -  ages 18 years or older&#xD;
&#xD;
          -  Subjects must have owned spectacles or contact lenses prior to enrolment for this&#xD;
             trial&#xD;
&#xD;
          -  spherical power between -10.00 D and +10.00 D (at vertex distance 0 mm)&#xD;
&#xD;
          -  astigmatic power equal to or less than 0.75 D&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  eye injury or surgery within 3 months immediately prior to enrolment for this trial&#xD;
&#xD;
          -  pre-existing ocular irritation that would preclude contact lens fitting&#xD;
&#xD;
          -  currently enrolled in an ophthalmic clinical trial&#xD;
&#xD;
          -  evidence of systemic or ocular abnormality, infection or disease which is likely to&#xD;
             affect successful wear of contact lenses use of as determined by the investigator&#xD;
&#xD;
          -  any use of medications for which contact lens wear could be contradicted, as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  current extended-wear users (sleep-in overnight)&#xD;
&#xD;
          -  current monovision leans wearers&#xD;
&#xD;
          -  pregnant women and nursing mothers&#xD;
&#xD;
          -  best-corrected visual acuity worse than 6/9 (logMAR: +0.20; Snellen decimal: 0.63)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Hartwig, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartwig Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Siehste</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kresinsky</name>
      <address>
        <city>WÃ¼rzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 19, 2014</study_first_submitted>
  <study_first_submitted_qc>September 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

